These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 26606114)

  • 21. Managing anemia: what do we do now?
    Neumann ME
    Nephrol News Issues; 2007 May; 21(6):50, 52. PubMed ID: 17518123
    [No Abstract]   [Full Text] [Related]  

  • 22. [Recent advances on the use of erythropoietin in oncology].
    Spaëth D
    Bull Cancer; 2006 May; 93(5):489-93. PubMed ID: 16777627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative studies on erythropoietic agents.
    Straus D
    J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S46-9. PubMed ID: 16280113
    [No Abstract]   [Full Text] [Related]  

  • 24. Utilizing quality of life as a factor in treatment choices for chemotherapy-induced anemia.
    Koopman W; Iakiri S
    J Support Oncol; 2005; 3(6 Suppl 4):20-1. PubMed ID: 16355554
    [No Abstract]   [Full Text] [Related]  

  • 25. Comment: Epoetin alfa versus darbepoetin alfa for cancer patients with treatment-related anemia.
    Yang MC
    Ann Pharmacother; 2006 May; 40(5):998-9; author reply 999. PubMed ID: 16670351
    [No Abstract]   [Full Text] [Related]  

  • 26. ESAs further restricted, but debate continues.
    Brower V
    J Natl Cancer Inst; 2008 Oct; 100(19):1344-51. PubMed ID: 18812542
    [No Abstract]   [Full Text] [Related]  

  • 27. Is anemia of cancer different from chemotherapy-induced anemia?
    Steensma DP
    J Clin Oncol; 2008 Mar; 26(7):1022-4. PubMed ID: 18227523
    [No Abstract]   [Full Text] [Related]  

  • 28. Long-acting erythropoietin stimulating agents for persistent anemia after kidney transplant: risk factors and outcome.
    Al-Otaibi T; Gheith O; Halim MA; Abu Attia H; Mansour H; Said T; Nair P; Balaha M; Nampoory MR
    Exp Clin Transplant; 2014 Jun; 12(3):220-6. PubMed ID: 24907722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting.
    Winkelmayer WC
    J Am Soc Nephrol; 2011 Jan; 22(1):1-2. PubMed ID: 21164031
    [No Abstract]   [Full Text] [Related]  

  • 30. FDA finalizes REMS program for ESAs; Amgen continues to study risks.
    Brower V
    J Natl Cancer Inst; 2010 May; 102(9):592-3. PubMed ID: 20421565
    [No Abstract]   [Full Text] [Related]  

  • 31. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression.
    Hedley BD; Allan AL; Xenocostas A
    Clin Cancer Res; 2011 Oct; 17(20):6373-80. PubMed ID: 21750199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does TREAT give the boot to ESAs in the treatment of CKD anemia?
    Singh AK
    J Am Soc Nephrol; 2010 Jan; 21(1):2-6. PubMed ID: 20035034
    [No Abstract]   [Full Text] [Related]  

  • 33. Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia.
    Lappin TR; Maxwell AP; Johnston PG
    Oncologist; 2007 Apr; 12(4):362-5. PubMed ID: 17470677
    [No Abstract]   [Full Text] [Related]  

  • 34. Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.
    Wauters I; Vansteenkiste J
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1383-90. PubMed ID: 23113603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Erythropoietin, chronic renal failure and cancer].
    Robles Perez-Monteoliva NR
    Med Clin (Barc); 2016 Jun; 146(12):539-40. PubMed ID: 26832198
    [No Abstract]   [Full Text] [Related]  

  • 36. [The treatment of chemotherapy-induced anemia in lung cancer patients].
    Gálffy G
    Magy Onkol; 2013 Mar; 57(1):39-49. PubMed ID: 23573521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents.
    Tanaka T; Nangaku M
    Exp Cell Res; 2012 May; 318(9):1068-73. PubMed ID: 22414872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anemia in cancer patients: significance, epidemiology, and current therapy.
    Tchekmedyian NS
    Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):17-24. PubMed ID: 12380951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a strategy to successfully convert an ambulatory infusion center from epoetin alfa to darbepoetin alfa.
    Longfield V; Gebhart B; Hayward L
    J Support Oncol; 2005; 3(6 Suppl 4):8-9. PubMed ID: 16355548
    [No Abstract]   [Full Text] [Related]  

  • 40. [Iron deficiency and anemia in oncology].
    Scotté F; Launay-Vacher V; Ray-Coquard I
    Bull Cancer; 2012 May; 99(5):563-70. PubMed ID: 22516641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.